A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic Seizures

Last updated: January 23, 2025
Sponsor: Eisai Co., Ltd.
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

No Intervention

Clinical Study ID

NCT06657378
E2007-M081-517
  • Ages > 4
  • All Genders

Study Summary

The purpose of this study is to determine the safety of Fycompa for injection after administration in participants with epilepsy (partial-onset seizures [including secondarily generalized seizures]) (age 4 years or older) or primary generalized tonic-clonic seizures (age 12 years or older).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants with epilepsy who received the Fycompa for injection for the first timewill be included.

Exclusion

Exclusion Criteria:

  • The exclusion criteria will not be specified in particular because this survey willbe conducted in daily clinical practice.

Study Design

Total Participants: 110
Treatment Group(s): 1
Primary Treatment: No Intervention
Phase:
Study Start date:
November 18, 2024
Estimated Completion Date:
June 30, 2028

Connect with a study center

  • 1

    Tokyo,
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.